~18 spots leftby Dec 2026

Endovascular Stent-Graft for Aortic Aneurysm

Recruiting at1 trial location
WJ
Overseen byWarren J Gasper, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Warren J. Gasper, MD
Disqualifiers: Pregnancy, Serious infection, Coagulopathy, others
No Placebo Group
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study is evaluating whether a stent-graft may help treat aortic aneurysms.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Endovascular Branched Stent-Graft, Fenestrated Endovascular Aneurysm Repair (FEVAR), Branched Endovascular Aneurysm Repair (BEVAR), Endovascular Aneurysm Repair (EVAR)?

Research shows that fenestrated and branched endovascular repairs (FEVAR and BEVAR) are effective for treating complex aortic aneurysms, such as those near the kidneys or involving the thoracic aorta. These techniques have been shown to be safe and feasible, with studies reporting positive midterm and long-term outcomes.12345

Is the endovascular stent-graft for aortic aneurysm generally safe for humans?

Research shows that endovascular stent-grafts, including fenestrated and branched types, are generally safe for treating aortic aneurysms, with studies reporting on technical success and manageable risks like acute kidney injury and spinal cord issues. These procedures are considered alternatives to open surgery, especially for complex cases, and have been evaluated for safety and feasibility in various studies.12467

How is the Endovascular Branched Stent-Graft treatment different from other treatments for aortic aneurysms?

The Endovascular Branched Stent-Graft treatment is unique because it uses a minimally invasive approach to repair complex aortic aneurysms by inserting a stent (a small mesh tube) with branches or openings (fenestrations) that allow blood flow to important arteries, unlike traditional open surgery which requires a large incision.12348

Research Team

WJ

Warren J Gasper, MD

Principal Investigator

University of California, San Francisco

Eligibility Criteria

This trial is for men and women with large aortic aneurysms (5.5 cm or more in diameter for women, 6 cm or more for men) including those that are growing quickly or have associated iliac aneurysms. Participants should expect to live at least two years, be able to consent, follow the study plan, and have suitable anatomy for the procedure. Pregnant individuals, those allergic to certain metals or materials used in stents, with uncontrolled bleeding disorders or serious infections cannot join.

Inclusion Criteria

Willingness to comply with follow-up schedule
I am a man with an aortic aneurysm 6 cm or larger.
My aortic aneurysm is at least 5.5 cm wide.
See 6 more

Exclusion Criteria

I have a blood clotting disorder that cannot be corrected.
Pregnancy
Known allergy to Nitinol, stainless steel, or polyester
See 3 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo endovascular treatment involving the placement of a stent-graft over the aortic aneurysm

1 week
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the endovascular treatment

12 weeks
3 visits (in-person)

Treatment Details

Interventions

  • Endovascular Branched Stent-Graft (Stent-Graft)
Trial OverviewThe trial tests a new endovascular treatment using a branched stent-graft placed over thoracoabdominal and paravisceral abdominal aortic aneurysms. It aims to evaluate how safe and effective this minimally invasive operation is compared to traditional surgery.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: InterventionalExperimental Treatment1 Intervention
Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).

Endovascular Branched Stent-Graft is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as Endovascular Aneurysm Repair (EVAR) for:
  • Abdominal aortic aneurysms (AAAs)
  • Thoracoabdominal aortic aneurysms (TAAAs)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Warren J. Gasper, MD

Lead Sponsor

Trials
1
Recruited
250+

Timothy Chuter, MD

Lead Sponsor

Trials
2
Recruited
280+

Findings from Research

In a study of 100 patients undergoing fenestrated or branched endovascular aortic repair (FEVAR/BEVAR), the primary technical success rate was 87%, indicating that this method is generally effective for treating complex aortic aneurysms.
The 30-day mortality rate was 6%, primarily due to myocardial infarction, emphasizing the need for careful preoperative risk assessment to improve patient outcomes.
Fenestrated and branched endovascular repair for juxtarenal and thoracoabdominal aortic aneurysms: analysis of the first 100 cases.Uijtterhaegen, G., VAN Langenhove, K., Moreels, N., et al.[2022]
A systematic review of 29 studies involving 693 cases of branched and fenestrated endografts (fEVAR/bEVAR) showed a high technical success rate of 96% in treating thoracic aorta pathologies, primarily aneurysms and dissections.
The main complications included a 5.2% rate of endoleaks and a 4.8% rate of strokes, with an in-hospital mortality of 2.5%, indicating that while these techniques are effective, there are notable risks that need to be managed.
The Initial Experience on Branched and Fenestrated Endografts in the Aortic Arch. A Systematic Review.Blanco Amil, CL., Mestres Alomar, G., Guarnaccia, G., et al.[2021]
In a study of 39 patients treated with the BeGraft stent graft system for fenestrated endovascular aneurysm repair (fEVAR), the bridging stents showed high patency rates of 98% at 1 year and 97% at 2 years, indicating effective long-term performance.
Despite a 28% mortality rate during follow-up, primarily from non-aneurysm-related causes, the BeGraft stents demonstrated a 96% freedom from secondary procedures, suggesting that they are a reliable option for connecting stent grafts to aortic branch vessels.
Midterm Outcomes of BeGraft Stent Grafts Used as Bridging Stents in Fenestrated Endovascular Aortic Aneurysm Repair.Clough, RE., Spear, R., Mougin, J., et al.[2023]

References

Fenestrated and branched endovascular repair for juxtarenal and thoracoabdominal aortic aneurysms: analysis of the first 100 cases. [2022]
The Initial Experience on Branched and Fenestrated Endografts in the Aortic Arch. A Systematic Review. [2021]
Midterm Outcomes of BeGraft Stent Grafts Used as Bridging Stents in Fenestrated Endovascular Aortic Aneurysm Repair. [2023]
Feasibility and Twelve-month Patency of a Six-fold Fenestrated Stent Graft for Type IV Thoracoabdominal Aneurysm Repair. [2020]
Long-term follow-up of fenestrated endovascular repair for juxtarenal aortic aneurysm. [2018]
Systematic review and meta-analysis on fenestrated or branched devices after previous open surgical aortic aneurysm repair. [2023]
Physician-Modified Fenestrated Endografts for Managing the Ruptured or Symptomatic Aortic Aneurysm: Technique Overview and Clinical Outcomes. [2018]
Fenestrated and Branched Aortic Grafts. [2018]